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Abs and reagents
The following mAbs were purchased from BD Biosciences: anti-CD45R/B220 PerCP and Pacific Blue (RA3-6B2), anti-IgG1 PE (A85-1), anti-CD4 FITC and APC (RM4-5), anti-CD16/CD32 (2.4G2), anti-CD45.2 biotin (104), anti-CXCR5 biotin (2G8), anti-PD1 PE (J43), GL7 FITC, streptavidin-FITC and streptavidin-APC. The following mAbs were purchased from eBiosciences: anti-CD11c APC (N418), anti-CD45.1 PE/Cy7 (A20), 
Flow cytometry
Cell suspensions from spleen were prepared and RBC were lysed. FcRs were blocked with unlabeled anti-CD16/32. Staining was carried out at 4ºC except CCR7 staining which was performed at 37ºC. Cells were filtered using 35µm filter round-bottom FACS tubes (BD Biosciences) immediately before data acquisition on either BD LSR II or FACSCanto analyzers. Cytometer files were acquired on Diva software (BD Biosciences) and analyzed with FlowJo software (TreeStar). Plots were gated on lymphocytes using forward scatter versus side scatter, followed by doublet exclusion. CD4 T cells were 
Anti-HEL ELISAs
Production of recombinant HEL 2X and HEL 3X proteins and anit-HEL ELISAs have been described previously (Paus et al., 2006; Phan et al., 2003 and 4-5 days later mice were sacrificed and spleens analysed by flow cytometry.
Staining of PBMC
Buffy coats from healthy donors were obtained from the Australian Red Cross Blood Service. Peripheral blood was collected from XLP and XLA patients who have been described previously (Ma et al., 2006; Suryani et al., 2010) . Cells were stained with anti-CXCR5 (BD Biosciences) and anti-CD4 (eBioscience). All studies were approved by the institutional Human Ethics Review Committees.
Statistical Analysis
Unpaired, two-tailed t-tests were carried out using Prism software (Graphpad).
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